×÷ΪÖйúµÚÈý·½¼ì²âÓëÈÏÖ¤·þÎñµÄ¿ªÍØÕߺÍÁìÏÈÕߣ¬NG28ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿¼ì²âΪȫÇò¿Í»§Ìṩһվʽ¼ìÑé¡¢²âÊÔ¡¢Ð£×¼¡¢ÈÏÖ¤¼°¼¼Êõ·þÎñ¡£
·þÎñÄÜÁ¦ÒÑÈ«ÃæÁýÕÖµ½·ÄÖ¯·þ×°¼°Ð¬°ü¡¢Ó¤Í¯Íæ¾ß¼°¼Ò¾ÓÉú»î¡¢µç×ÓµçÆ÷¡¢Ò½Ñ§½¡¿µ¡¢Ê³Æ·¼°Å©²úÎï……µÈÐÐÒµµÄ¹©Ó¦Á´ÉÏÏÂÓΡ£
È«Ãæ±£ÕÏÆ·ÖÊÓëÄþ¾²£¬Íƶ¯ºÏ¹æÓ봴У¬ÕÃÏÔÆ·ÅƾºÕùÁ¦£¬ÊµÏÖ¸ü¸ßÖÊÁ¿¡¢¸ü½¡¿µ¡¢¸üÄþ¾²¡¢¸üÂÌÉ«µÄ¿ÉÁ¬ÐøÉú³¤¡£
ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿ÉúÎï¿Éƾ¾ÝÖ¸µ¼ÔÔòÒªÇ󣬿ªÕ¹ÏµÍ³µÄÒ©´ú¶¯Á¦Ñ§Ñо¿£¬°üÂÞÌåÄÚÒ©´úºÍÌåÍâÒ©´ú¡£
ÌåÄÚ´úлIn vivo metabolism
1£©Ò©ÎïÎüÊÕ¡¢ÂþÑÜ¡¢´úлÓëÅÅÐ¹ÌØÐÔ±íÕ÷ Absorption, distribution, metabolism and excretion(ADME)
2£©Ò©ÎïÌåÄÚ¹ý³Ì¼°Ö÷ÒªÒ©¶¯Ñ§²ÎÊý Intracorporal process of drugs and major PK parameter
3£©ÉúÎïÀûÓöÈBioavailability
4£©ÉúÎïµÈЧÐÔBioequivalence
ÌåÍâ´úл In vitro metabolism
1£©È˺Ͷ¯ÎïµÄ´úлÎȶ¨ÐÔ Species variation in metabolism
2£©Ò©Îï´úлÏ໥×÷Óà Drug-drug interactions
3£©Ò©ÎïתÔËÌØÐÔDrug absorption and kinetics
4£©Ñª½¬ÂѰ׽áºÏProtein binding
5£©´úл²úÎï·ÖÎöMetabolite identification, stability, and profile
·þÎñÓÅÊÆ
²¡ÀíʵÑéÊÒ
ÌṩÇкÏGLP¹æ·¶µÄ½âÆÊ¼°×éÖ¯²¡ÀíÑо¿£¬°üÂÞÄö³ÝÀàºÍ·ÇÄö³ÝÀදÎïµÄ½âÆÊ£¬×éÖ¯ÔàÆ÷µÄÈ¡²Ä¡¢°üÂñ¡¢ÇÐÆ¬¡¢Í¨ÀýȾɫ¡¢ÌØÊâȾɫ¼°ÃâÒß×éÖ¯»¯Ñ§È¾É«£¬ÖÐÓ¢ÎÄ×éÖ¯²¡ÀíѧÕï¶Ï¼°³ÂËß
ÁÙ´²¼ìÑéÊÒ
ÂôÁ¦½øÐж¯ÎïµÄѪҺѧ¼ì²é¡¢ÑªÉú»¯¼ì²é¡¢ÑªÄý¹¦Ð§¼ì²é¡¢¹ÇËèÐÎ̬ѧ¼ì²é¼°ÄòÒº¼ì²é¡£Ö÷ÒªÒÇÆ÷É豸ÓУºSiemens ADVIA 2120i¶¯ÎïÓÃÎå·ÖÀàÈ«×Ô¶¯ÑªÒº·ÖÎöÒÇ£¬Roche Cobas 6000 C501È«×Ô¶¯Éú»¯·ÖÎöÒÇ£¬Sysmex CA-7000È«×Ô¶¯ÑªÄýÒÇ£¬AUTION MAX AX-4030ÄòÑù·ÖÎöÒÇ¡¢BD FACS CaliburÁ÷ʽϸ°ûÒÇ¡¢CHRONO-LOG 700ѪС°å¾Û¼¯ÒÇ¡£
¹©ÊÔÆ·¹ÜÀíÊÒ
ÓµÓй©ÊÔÆ·¹ÜÀíÊÒ¡¢¹©ÊÔÆ·ÅäÖÆÊÒ¡¢¹©ÊÔÆ·´æ·ÅÊÒ¡£Æ¾¾ÝGLPºÍSOPµÄÒªÇó£¬ÊµÊ©¶Ô¹©ÊÔÆ·¡¢¶ÔÕÕÆ·¼°ÊÔÑéÏà¹ØÊÔ¼Á¡¢Ò©Æ·µÄ¹ÜÀí£¬¶Ô¹©ÊÔÆ·µÄ½ÓÊÕ¡¢Éú´æ¡¢ÅäÖÆ¡¢·ÖÎö¡¢·¢·Å¡¢»ØÊÕ¼°¹éµµµÈ¶à¸ö»·½Ú½øÐпØÖƺ͹ÜÀí¡£
·ÖÎö²âÊÔÊÒ
·ÖÎö²âÊÔ²¿×÷Ϊ¹«Ë¾ºËÐIJ¿ÃÅÖ®Ò»£¬ÒÀ¿¿×¨ÒµµÄ²âÊԼƻ®¡¢ÏȽøµÄʵÑéÉ豸(UPLC¡¢LC/MS/MS¡¢PE¶à±êλ¼ì²âÒÇ)ºÍ¶àÄêµÄÐÐÒµÁìÏȾÑ飬 Ö÷ҪΪ¹úÄÚÍâ¿Í»§Ìṩ¶¾´ú/Ò©´úÑùÆ·µÄ·ÖÎö¼ì²â·þÎñ£¬²¢ÄÜÕë¶Ô¿Í»§µÄ¾ßÌåÒªÇóΪÆäÁ¿Éí¶¨×öÊÊÒ˵Ľâ¾ö·½°¸¡£
¶¯Îï·¿
ƾ¾Ý¹ú¼Ò³ß¶È½¨³É£¬ÓµÓÐSPF¼¶ºÍÆÕͨ¼¶¶¯ÎïÉèÊ©ÒÔ¼°Î¢ÉúÎï¼ì²âÊÒ¡£½ÓÄÉJonson ControlsϵͳÖÇÄÜ»¯¿ØÖƶ¯ÎïÉèÊ©µÄζȡ¢Êª¶È¡¢Ñ¹²î£¬²¢ÄÜʵÏÖ¶Ô¶¯ÎïÉèÊ©¼°¸¨ÖúÉèÊ©24СʱÄþ¾²¼à¿Ø¼°±¨¾¯¡£